Dana N, Dabiri A, Najafi M, Rahimi A, Ishaghi S, Shariati L
Bioeng Transl Med. 2025; 10(2):e10716.
PMID: 40060757
PMC: 11883117.
DOI: 10.1002/btm2.10716.
Kertmen N, Kavgaci G, Koc I, Sagol S, Isikay A, Yazici G
Oncol Lett. 2025; 29(3):146.
PMID: 39877061
PMC: 11773301.
DOI: 10.3892/ol.2025.14892.
Yuan H, Cheng J, Xia J, Yang Z, Xu L
Discov Oncol. 2025; 16(1):35.
PMID: 39800804
PMC: 11725551.
DOI: 10.1007/s12672-024-01653-2.
Kumar M, Nassour-Caswell L, Alrefai H, Anderson J, Schanel T, Hicks P
Cells. 2024; 13(23).
PMID: 39682742
PMC: 11640616.
DOI: 10.3390/cells13231995.
Yoel A, Adjumain S, Liang Y, Daniel P, Firestein R, Tsui V
Cells. 2024; 13(17.
PMID: 39273062
PMC: 11394548.
DOI: 10.3390/cells13171492.
Zonulin as Gatekeeper in Gut-Brain Axis: Dysregulation in Glioblastoma.
Hagemeyer H, Hellwinkel O, Plata-Bello J
Biomedicines. 2024; 12(8).
PMID: 39200114
PMC: 11352073.
DOI: 10.3390/biomedicines12081649.
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.
Ser M, Webb M, Sener U, Campian J
J Immunother Precis Oncol. 2024; 7(2):97-110.
PMID: 38721406
PMC: 11075475.
DOI: 10.36401/JIPO-23-34.
Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion.
Yu K, Yuan W, Wang H, Li Y
Cancer Immunol Immunother. 2024; 73(6):115.
PMID: 38693304
PMC: 11063025.
DOI: 10.1007/s00262-024-03675-9.
Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
Repici A, Ardizzone A, Luca F, Colarossi L, Prestifilippo A, Pizzino G
Cells. 2024; 13(4.
PMID: 38391974
PMC: 10886920.
DOI: 10.3390/cells13040361.
Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma.
Gardam B, Gargett T, Brown M, Ebert L
Front Immunol. 2023; 14:1261257.
PMID: 37928547
PMC: 10623138.
DOI: 10.3389/fimmu.2023.1261257.
Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas.
Jucht A, Dumont S, Pooley C, Gonzalez Castro L
Ther Adv Vaccines Immunother. 2023; 11:25151355231206163.
PMID: 37886714
PMC: 10599115.
DOI: 10.1177/25151355231206163.
Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
Hansch L, Peipp M, Mastall M, Villars D, Myburgh R, Silginer M
Neuro Oncol. 2023; 25(11):2001-2014.
PMID: 37335916
PMC: 10628943.
DOI: 10.1093/neuonc/noad108.
Immunotherapy in glioblastoma treatment: Current state and future prospects.
Rocha Pinheiro S, Bueno Lemos F, Marques H, Silva Luz M, de Oliveira Silva L, Faria Souza Mendes Dos Santos C
World J Clin Oncol. 2023; 14(4):138-159.
PMID: 37124134
PMC: 10134201.
DOI: 10.5306/wjco.v14.i4.138.
CAR T cells: engineered immune cells to treat brain cancers and beyond.
Huang Z, Dewanjee S, Chakraborty P, Jha N, Dey A, Gangopadhyay M
Mol Cancer. 2023; 22(1):22.
PMID: 36721153
PMC: 9890802.
DOI: 10.1186/s12943-022-01712-8.
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Schatz J, Ladinig A, Fietkau R, Putz F, Gaipl U, Frey B
Strahlenther Onkol. 2022; 199(12):1140-1151.
PMID: 36480032
PMC: 10673751.
DOI: 10.1007/s00066-022-02028-8.
Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo.
Blomberg E, Silginer M, Roth P, Weller M
Neurooncol Adv. 2022; 4(1):vdac148.
PMID: 36212740
PMC: 9536295.
DOI: 10.1093/noajnl/vdac148.
Current understanding of the human microbiome in glioma.
Liang J, Li T, Zhao J, Wang C, Sun H
Front Oncol. 2022; 12:781741.
PMID: 36003766
PMC: 9393498.
DOI: 10.3389/fonc.2022.781741.
The Interplay of Four Main Pathways Recomposes Immune Landscape in Primary and Metastatic Gastroenteropancreatic Neuroendocrine Tumors.
Lou X, Gao H, Xu X, Ye Z, Zhang W, Wang F
Front Oncol. 2022; 12:808448.
PMID: 35664743
PMC: 9158120.
DOI: 10.3389/fonc.2022.808448.
Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.
Liang R, Wu C, Liu S, Zhao W
Drug Deliv. 2022; 29(1):1620-1630.
PMID: 35612318
PMC: 9135425.
DOI: 10.1080/10717544.2022.2075986.
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
McAleavey P, Walls G, Chalmers A
CNS Oncol. 2022; 11(2):CNS86.
PMID: 35603818
PMC: 9134931.
DOI: 10.2217/cns-2021-0015.